Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today shared new preclinical data for ...

Anti-IL1RAP ADC demonstrated potent anti-tumor efficacy and was well tolerated in pre-clinical models Anti-IL1RAP ADC targets ...

Treatment with an Enhertu regimen significantly improved pathologic complete responses for patients with high-risk ...

Lotte Biologics, the biotech arm of Lotte Group, said on Thursday it has signed a deal with an Asia-based biotech company for ...

Patients who are immunocompromised still can receive a variety of vaccinations based on their specific needs, Cassandra ...

Serina Therapeutics, Inc.’s SER share price has surged by 9.23%, which has investors questioning if this is right time to ...

The Cancer Pioneers” has just dropped, giving audiences a moving first look at the groundbreaking new documentary that ...

Researchers investigated the combined effects of bazedoxifene and conjugated estrogens in rat models as an alternative to tamoxifen.

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the clearance of an investigational new ...

PALO ALTO, CA, UNITED STATES, April 25, 2025 /EINPresswire.com/ -- Preclinical results for lead ADC candidate BLB-101 for Claudin 6/9+ tumors supports potential best-in-class profile. Data presented ...